CM3.1-AC100

DRUG3 trials

Sponsors

CellMed AG, a subsidiary of BTG plc.

Conditions

HealthyType II Diabetes Mellitus

Phase 1

First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

CompletedNCT01028521

CellMed AG, a subsidiary of BTG plc.Healthy

Start: 2010-02-28End: 2010-05-31Target: 56Updated: 2010-07-15

Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

CompletedNCT01165502

CellMed AG, a subsidiary of BTG plc.Healthy

Start: 2010-07-31End: 2010-11-30Target: 40Updated: 2011-01-19

Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes

CompletedNCT01196728

CellMed AG, a subsidiary of BTG plc.Type II Diabetes Mellitus

Start: 2010-09-30End: 2010-11-30Target: 16Updated: 2010-12-06